Merck to invest $1 billion in U.S. drug manufacturing plant

Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing. 

The move comes amid plans by President Trump to impose tariffs on pharmaceuticals, which would include taxes on imported ingredients used in the making of such medicines.

The drug maker on Tuesday announced a new 470,000-square-foot facility in Wilmington, Delaware, where it will make Keytruda, the company's immunotherapy treatment for different cancers. The plant will be Merck's first U.S. facility dedicated to making Keytruda for U.S. patients, the company said.